RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM in advanced clinical development to treat severe COVID-19 patients, announced the appointment of J. Paul Waymack, M.D., Sc.D. as development and regulatory consultant.
November 4, 2020
· 4 min read